Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diwu is a traditional Chinese herbal medicine derived from the dried rhizome of *Anemone flaccida* Fr. Schmidt. It is rich in triterpenoid saponins, which exhibit anti-inflammatory, anti-rheumatic, and anti-tumor properties. Diwu has been traditionally used to treat joint pain, fractures, and rheumatoid arthritis. Modern pharmacological studies have shown that Diwu extract can suppress myeloma bone disease by targeting the CCL3/ERK/MAPK signaling pathway, inhibiting myeloma cell proliferation, and suppressing osteoclastogenesis. It is being developed for the treatment of rheumatoid arthritis and multiple myeloma-associated bone disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diwu.